摘要
目的:研究NM-23,COX-2在胃癌FOLFOX方案新辅助化疗前后的变化,探讨其作为新辅助化疗预测因子的可能性。方法:对95例局限进展期胃癌患者行FOLFOX-4方案新辅助化疗。新辅助化疗应用4个周期,共有85例患者完成新辅助化疗并接受了根治性或姑息性手术。免疫组织化学染色检测NM-23、COX-2的表达情况,并对比术前活检组织与术后切除标本中两种蛋白表达变化。结果:本组病例观察临床缓解率58.2%,疾病控制率90.1%。术前活检组织中NM-23阳性表达及COX-2阴性表达与化疗显效有关。新辅助化疗及术后,NM-23表达上升,COX-2表达下降。临床缓解组病例NM-23上升及COX-2下降均较临床未缓解病例显著(P<0.05)。结论:对FOLFOX新辅助化疗方案敏感的胃癌病例具有NM-23高表达、COX-2低表达的特点。此外,NM-23表达上调及COX-2表达降低可能与化疗显效有关。NM-23、COX-2可能作为新辅助化疗敏感人群的筛选指标和疗效判定指标。
Objective：To investigate NM-23 and COX-2 expression alternations by FOLFOX neoadjuvant chemotherapy in gastric cancer,and discuss its clinical significance.Methods：Neoadjuvant chemotherapy of FOLFOX regimen was undertaken in 85 gastric cancer patients.The expression of NM-23 and COX-2 were evaluated by immunohistochemistry staining.The therapeutic response was evaluated by CT scan according to RECIST criteria.Results：In the group exhibited clinical response（CR＋PR）,the expression of NM-23 was significantly higher than that in the non-response（SD＋PD） group.After neoadjuvant chemotherapy NM-23 expression was elevated in both groups,but there was more prominent in the response group（P0.05）.The expression of COX-2 was lower in the response group before chemotherapy.The COX-2 expression reduced more significant in the response group than that in the non-response group.Conclusion：The clinically response group was characterized by a high expression of NM-23 and low expression of COX-2.The elevation of NM-23 and reduction of COX-2 were related with chemotherapy-sensitivity.NM-23 and COX-2 might be use as chemosensitive markers and indicators of theraputic response.
出处
《现代生物医学进展》
CAS
2012年第36期7061-7065,共5页
Progress in Modern Biomedicine
基金
辽宁省"百千万人才工程"培养经费(2010920137)
辽宁省自然科学基金(201102110)
国家人力资源社会保障部留学人员科技活动项目择优资助(2011LX005)
